-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Central point | Cancer, central venous catheters, older age and MIS-C are all risk factors for thrombosis in children and adolescents with new coronary pneumonia or MIS-C ; mortality in children and adolescents with MIS-C or new coronary pneumonia with thrombosis Very high (28%) .
Central point | Cancer, central venous catheters, older age and MIS-C are all risk factors for thrombosis in children and adolescents with new coronary pneumonia or MIS-C ; mortality in children and adolescents with MIS-C or new coronary pneumonia with thrombosis Very high (28%) .The center point of the new crown pneumonia Children thrombosis
The new coronary pneumonia ( COVID-19 ) caused by the new coronary pneumonia virus (SARS-CoV-2) is related to adult thrombosis complications, but the incidence of new coronary pneumonia-related thrombosis in children and adolescents is unclear
.
Most children with acute new coronary pneumonia are mildly ill, but coagulation dysfunction is associated with multiple system inflammatory syndrome (MIS-C, a post - infection complication) in children
.
Researchers such as Whitworth conducted a multi-center retrospective cohort study to determine the incidence of thrombosis in hospitalized children with new coronary pneumonia or MIS-C, and to assess related risk factors
.
Researchers divided the children into 3 groups for analysis: the new coronary pneumonia group, the MIS-C group or the asymptomatic infection group
.
Receiving dosage strength divided by clinical subgroups preventing patients proportionality anticoagulation
Divided by the dose strength clinical subgroups receiving prevention proportion of patients anticoagulation prophylaxisA total of 814 patients were enrolled and a total of 853 hospitalizations (426 cases of new coronary pneumonia, 138 cases of MIS-C, and 289 cases of asymptomatic infection), of which 20 children had thrombotic events (TE; including one stroke )
.
Compared with new coronary pneumonia or asymptomatic infection, children with MIS-C have the highest thrombosis rate (MIS-C vs COVID-19 vs asymptomatic infection: 6.
5% [9 cases] vs 2.
1% [9 cases] vs 0.
7% [2 cases ])
Compared with new coronary pneumonia or asymptomatic infection, stroke children with MIS-C have the highest thrombosis rate (MIS-C vs.
Preventive anticoagulation program for children with new coronary pneumonia or MIS-C
Preventive anticoagulation program for children with new coronary pneumonia or MIS-CAmong children with new coronary pneumonia or MIS-C, most TE (89%) occurred in children ≥12 years of age
.
Children with MIS-C ≥12 years of age have the highest thrombosis rate, as high as 19% (9/48)
.
Among children with new coronary pneumonia or MIS-C, most TE (89%) occurred in children ≥12 years of age
Factors that are significantly related to thrombosis are: children with ≥12 years of age, cancer, central venous catheters, and MIS-C new coronary pneumonia or MIS-C.
Original source:
Original source:Hilary Whitworth, et al.
Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C in this message
